Key Points
- Jeff Castelli sold 76,158 Amicus shares on November 24 at an average price of $10.16 for about $773,765, cutting his position by 14.77% to 439,318 shares (valued ≈ $4.46M).
- Company performance and outlook: Amicus beat the quarter with $0.17 EPS vs $0.12 and $169.06M revenue (up 19.5% YoY), trades near its 52‑week high (~$10), has a $3.09B market cap, and carries a consensus "Moderate Buy" rating with an average target of $16.57.
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 14,587 shares of the company's stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $10.04, for a total value of $146,453.48. Following the completion of the sale, the chief executive officer owned 1,137,282 shares of the company's stock, valued at approximately $11,418,311.28. The trade was a 1.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Amicus Therapeutics Price Performance
Amicus Therapeutics stock traded up $0.15 during mid-day trading on Thursday, hitting $10.02. The stock had a trading volume of 3,136,374 shares, compared to its average volume of 4,236,660. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The firm's 50 day moving average is $8.73 and its 200 day moving average is $7.34. The firm has a market capitalization of $3.09 billion, a P/E ratio of -83.49 and a beta of 0.66. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $10.57.
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The business's quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently commented on FOLD. Zacks Research upgraded Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 6th. Wall Street Zen raised shares of Amicus Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 8th. Needham & Company LLC upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 target price for the company in a research report on Thursday, September 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Amicus Therapeutics in a report on Tuesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an "overweight" rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.57.
Read Our Latest Stock Analysis on Amicus Therapeutics
Institutional Investors Weigh In On Amicus Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Vestal Point Capital LP increased its position in shares of Amicus Therapeutics by 178.4% during the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company's stock worth $68,187,000 after purchasing an additional 7,625,000 shares in the last quarter. Nuveen LLC purchased a new position in Amicus Therapeutics during the 1st quarter worth approximately $28,741,000. Norges Bank purchased a new stake in Amicus Therapeutics in the second quarter valued at $18,540,000. Assenagon Asset Management S.A. grew its holdings in Amicus Therapeutics by 641.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company's stock worth $20,249,000 after acquiring an additional 3,057,072 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Amicus Therapeutics by 635.1% during the 1st quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company's stock worth $27,413,000 after purchasing an additional 2,902,375 shares during the period.
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
